-
1
-
-
84918815964
-
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
-
1 [PMID: 25220842]
-
1 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
-
(2015)
Int J Cancer
, vol.136
, pp. E359-E386
-
-
Ferlay, J1
Soerjomataram, I2
Dikshit, R3
Eser, S4
Mathers, C5
Rebelo, M6
Parkin, DM7
Forman, D8
Bray, F.9
-
2
-
-
35148834395
-
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006
-
2 Suppl 7: [PMID: 17600091]
-
2 Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol 2007; 18 Suppl 7: vii1-vii10 [PMID: 17600091 DOI: 10.1093/annonc/mdm210]
-
(2007)
Ann Oncol
, vol.18
, pp. vii1-vii10
-
-
Verslype, C1
Van Cutsem, E2
Dicato, M3
Cascinu, S4
Cunningham, D5
Diaz-Rubio, E6
Glimelius, B7
Haller, D8
Haustermans, K9
Heinemann, V10
Hoff, P11
Johnston, PG12
Kerr, D13
Labianca, R14
Louvet, C15
Minsky, B16
Moore, M17
Nordlinger, B18
Pedrazzoli, S19
Roth, A20
Rothenberg, M21
Rougier, P22
Schmoll, HJ23
Tabernero, J24
Tempero, M25
van de Velde, C26
Van Laethem, JL27
Zalcberg, J.28
more..
-
3
-
-
77951755278
-
Pancreatic cancer
-
3 [PMID: 20427809]
-
3 Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617 [PMID: 20427809 DOI: 10.1056/NEJMra0901557]
-
(2010)
N Engl J Med
, vol.362
, pp. 1605-1617
-
-
Hidalgo, M.1
-
4
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
-
4 [PMID: 9196156]
-
4 Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413 [PMID: 9196156]
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris, HA1
Moore, MJ2
Andersen, J3
Green, MR4
Rothenberg, ML5
Modiano, MR6
Cripps, MC7
Portenoy, RK8
Storniolo, AM9
Tarassoff, P10
Nelson, R11
Dorr, FA12
Stephens, CD13
Von Hoff, DD.14
-
5
-
-
77949264996
-
Advanced pancreatic carcinoma: current treatment and future challenges
-
5 [PMID: 20101258]
-
5 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7: 163-172 [PMID: 20101258 DOI: 10.1038/nrclinonc.2009.236]
-
(2010)
Nat Rev Clin Oncol
, vol.7
, pp. 163-172
-
-
Stathis, A1
Moore, MJ.2
-
6
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
6 [PMID: 17452677]
-
6 Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966 [PMID: 17452677 DOI: 10.1200/ JCO.2006.07.9525]
-
(2007)
J Clin Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, MJ1
Goldstein, D2
Hamm, J3
Figer, A4
Hecht, JR5
Gallinger, S6
Au, HJ7
Murawa, P8
Walde, D9
Wolff, RA10
Campos, D11
Lim, R12
Ding, K13
Clark, G14
Voskoglou-Nomikos, T15
Ptasynski, M16
Parulekar, W.17
-
7
-
-
83355169753
-
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
-
7 [PMID: 21969517]
-
7 Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29: 4548-4554 [PMID: 21969517 DOI: 10.1200/JCO.2011.36.5742]
-
(2011)
J Clin Oncol
, vol.29
, pp. 4548-4554
-
-
Von Hoff, DD1
Ramanathan, RK2
Borad, MJ3
Laheru, DA4
Smith, LS5
Wood, TE6
Korn, RL7
Desai, N8
Trieu, V9
Iglesias, JL10
Zhang, H11
Soon-Shiong, P12
Shi, T13
Rajeshkumar, NV14
Maitra, A15
Hidalgo, M.16
-
8
-
-
80052142960
-
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
-
8 ; author reply 769 [PMID: 21864184]
-
8 Vaccaro V, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 365: 768-779; author reply 769 [PMID: 21864184 DOI: 10.1056/NEJMc1107627]
-
(2011)
N Engl J Med
, vol.365
, pp. 768-779
-
-
Vaccaro, V1
Sperduti, I2
Milella, M.3
-
9
-
-
52149123619
-
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
-
9 [PMID: 18772397]
-
9 Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806 [PMID: 18772397 DOI: 10.1126/ science.1164368]
-
(2008)
Science
, vol.321
, pp. 1801-1806
-
-
Jones, S1
Zhang, X2
Parsons, DW3
Lin, JC4
Leary, RJ5
Angenendt, P6
Mankoo, P7
Carter, H8
Kamiyama, H9
Jimeno, A10
Hong, SM11
Fu, B12
Lin, MT13
Calhoun, ES14
Kamiyama, M15
Walter, K16
Nikolskaya, T17
Nikolsky, Y18
Hartigan, J19
Smith, DR20
Hidalgo, M21
Leach, SD22
Klein, AP23
Jaffee, EM24
Goggins, M25
Maitra, A26
Iacobuzio-Donahue, C27
Eshleman, JR28
Kern, SE29
Hruban, RH30
Karchin, R31
Papadopoulos, N32
Parmigiani, G33
Vogelstein, B34
Velculescu, VE35
Kinzler, KW.36
more..
-
10
-
-
0024292722
-
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
-
10 [PMID: 2453289]
-
10 Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554 [PMID: 2453289 DOI: 10.1016/0092-8674(88)90571-5]
-
(1988)
Cell
, vol.53
, pp. 549-554
-
-
Almoguera, C1
Shibata, D2
Forrester, K3
Martin, J4
Arnheim, N5
Perucho, M.6
-
11
-
-
14444284330
-
Tumor-suppressive pathways in pancreatic carcinoma
-
11 [PMID: 9135016]
-
11 Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734 [PMID: 9135016]
-
(1997)
Cancer Res
, vol.57
, pp. 1731-1734
-
-
Rozenblum, E1
Schutte, M2
Goggins, M3
Hahn, SA4
Panzer, S5
Zahurak, M6
Goodman, SN7
Sohn, TA8
Hruban, RH9
Yeo, CJ10
Kern, SE11
-
12
-
-
13444274253
-
Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis
-
12 [PMID: 15720814]
-
12 Löhr M, Klöppel G, Maisonneuve P, Lowenfels AB, Lüttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005; 7: 17-23 [PMID: 15720814 DOI: 10.1593/neo.04445]
-
(2005)
Neoplasia
, vol.7
, pp. 17-23
-
-
Löhr, M1
Klöppel, G2
Maisonneuve, P3
Lowenfels, AB4
Lüttges, J.5
-
13
-
-
77954554630
-
Clinical relevance of KRAS in human cancers
-
13 [PMID: 20617134]
-
13 Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010; 2010: 150960 [PMID: 20617134 DOI: 10.1155/2010/150960]
-
(2010)
J Biomed Biotechnol
, vol.2010
, pp. 150960
-
-
Jancík, S1
Drábek, J2
Radzioch, D3
Hajdúch, M.4
-
14
-
-
0032541650
-
Increasing complexity of Ras signaling
-
14 [PMID: 9779987]
-
14 Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-1413 [PMID: 9779987 DOI: 10.1038/sj.onc.1202174]
-
(1998)
Oncogene
, vol.17
, pp. 1395-1413
-
-
Campbell, SL1
Khosravi-Far, R2
Rossman, KL3
Clark, GJ4
Der, CJ.5
-
15
-
-
0037805547
-
RAS oncogenes: the first 30 years
-
15 [PMID: 12778136]
-
15 Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-465 [PMID: 12778136 DOI: 10.1038/nrc1097]
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 459-465
-
-
Malumbres, M1
Barbacid, M.2
-
16
-
-
0028059330
-
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
-
16 [PMID: 7726912]
-
16 Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32 [PMID: 7726912 DOI: 10.1038/ng0994-27]
-
(1994)
Nat Genet
, vol.8
, pp. 27-32
-
-
Caldas, C1
Hahn, SA2
da Costa, LT3
Redston, MS4
Schutte, M5
Seymour, AB6
Weinstein, CL7
Hruban, RH8
Yeo, CJ9
Kern, SE.10
-
17
-
-
16944367477
-
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas
-
17 [PMID: 9242437]
-
17 Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130 [PMID: 9242437]
-
(1997)
Cancer Res
, vol.57
, pp. 3126-3130
-
-
Schutte, M1
Hruban, RH2
Geradts, J3
Maynard, R4
Hilgers, W5
Rabindran, SK6
Moskaluk, CA7
Hahn, SA8
Schwarte-Waldhoff, I9
Schmiegel, W10
Baylin, SB11
Kern, SE12
Herman, JG.13
-
18
-
-
0032532379
-
Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression
-
18 [PMID: 9788631]
-
18 Wilentz RE, Geradts J, Maynard R, Offerhaus GJ, Kang M, Goggins M, Yeo CJ, Kern SE, Hruban RH. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 1998; 58: 4740-4744 [PMID: 9788631]
-
(1998)
Cancer Res
, vol.58
, pp. 4740-4744
-
-
Wilentz, RE1
Geradts, J2
Maynard, R3
Offerhaus, GJ4
Kang, M5
Goggins, M6
Yeo, CJ7
Kern, SE8
Hruban, RH.9
-
19
-
-
0030988302
-
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma
-
19 [PMID: 9187111]
-
19 Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997; 57: 2140-2143 [PMID: 9187111]
-
(1997)
Cancer Res
, vol.57
, pp. 2140-2143
-
-
Moskaluk, CA1
Hruban, RH2
Kern, SE.3
-
20
-
-
0024387728
-
Mutations in the p53 gene occur in diverse human tumour types
-
20 [PMID: 2531845]
-
20 Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-708 [PMID: 2531845 DOI: 10.1038/342705a0]
-
(1989)
Nature
, vol.342
, pp. 705-708
-
-
Nigro, JM1
Baker, SJ2
Preisinger, AC3
Jessup, JM4
Hostetter, R5
Cleary, K6
Bigner, SH7
Davidson, N8
Baylin, S9
Devilee, P.10
-
21
-
-
0026334753
-
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
-
21 [PMID: 1764370]
-
21 Barton CM, Staddon SL, Hughes CM, Hall PA, O’Sullivan C, Klöppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-1082 [PMID: 1764370 DOI: 10.1038/bjc.1991.467]
-
(1991)
Br J Cancer
, vol.64
, pp. 1076-1082
-
-
Barton, CM1
Staddon, SL2
Hughes, CM3
Hall, PA4
O’Sullivan, C5
Klöppel, G6
Theis, B7
Russell, RC8
Neoptolemos, J9
Williamson, RC.10
-
22
-
-
0028308492
-
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions
-
22 [PMID: 8187092]
-
22 Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-3033 [PMID: 8187092]
-
(1994)
Cancer Res
, vol.54
, pp. 3025-3033
-
-
Redston, MS1
Caldas, C2
Seymour, AB3
Hruban, RH4
da Costa, L5
Yeo, CJ6
Kern, SE.7
-
23
-
-
0030593038
-
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
-
23 [PMID: 8553070]
-
23 Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353 [PMID: 8553070 DOI: 10.1126/science.271.5247.350]
-
(1996)
Science
, vol.271
, pp. 350-353
-
-
Hahn, SA1
Schutte, M2
Hoque, AT3
Moskaluk, CA4
da Costa, LT5
Rozenblum, E6
Weinstein, CL7
Fischer, A8
Yeo, CJ9
Hruban, RH10
Kern, SE.11
-
24
-
-
0034032009
-
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression
-
24 [PMID: 10766191]
-
24 Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-2006 [PMID: 10766191]
-
(2000)
Cancer Res
, vol.60
, pp. 2002-2006
-
-
Wilentz, RE1
Iacobuzio-Donahue, CA2
Argani, P3
McCarthy, DM4
Parsons, JL5
Yeo, CJ6
Kern, SE7
Hruban, RH.8
-
25
-
-
0035004797
-
Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis
-
25 [PMID: 11337365]
-
25 Lüttges J, Galehdari H, Bröcker V, Schwarte-Waldhoff I, Henne- Bruns D, Klöppel G, Schmiegel W, Hahn SA. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001; 158: 1677-1683 [PMID: 11337365 DOI: 10.1016/S0002-9440(10)64123-5]
-
(2001)
Am J Pathol
, vol.158
, pp. 1677-1683
-
-
Lüttges, J1
Galehdari, H2
Bröcker, V3
Schwarte-Waldhoff, I4
Henne- Bruns, D5
Klöppel, G6
Schmiegel, W7
Hahn, SA.8
-
26
-
-
84869091997
-
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
-
26 [PMID: 23103869]
-
26 Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Australian Pancreatic Cancer Genome I, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399-405 [PMID: 23103869 DOI: 10.1038/nature11547]
-
(2012)
Nature
, vol.491
, pp. 399-405
-
-
Biankin, AV1
Waddell, N2
Kassahn, KS3
Gingras, MC4
Muthuswamy, LB5
Johns, AL6
Miller, DK7
Wilson, PJ8
Patch, AM9
Wu, J10
Chang, DK11
Cowley, MJ12
Gardiner, BB13
Song, S14
Harliwong, I15
Idrisoglu, S16
Nourse, C17
Nourbakhsh, E18
Manning, S19
Wani, S20
Gongora, M21
Pajic, M22
Scarlett, CJ23
Gill, AJ24
Pinho, AV25
Rooman, I26
Anderson, M27
Holmes, O28
Leonard, C29
Taylor, D30
Wood, S31
Xu, Q32
Nones, K33
Fink, JL34
Christ, A35
Bruxner, T36
Cloonan, N37
Kolle, G38
Newell, F39
Pinese, M40
Mead, RS41
Humphris, JL42
Kaplan, W43
Jones, MD44
Colvin, EK45
Nagrial, AM46
Humphrey, ES47
Chou, A48
Chin, VT49
Chantrill, LA50
Mawson, A51
Samra, JS52
Kench, JG53
Lovell, JA54
Daly, RJ55
Merrett, ND56
Toon, C57
Epari, K58
Nguyen, NQ59
Barbour, A60
Zeps, N61
Australian Pancreatic Cancer Genome, I62
Kakkar, N63
Zhao, F64
Wu, YQ65
Wang, M66
Muzny, DM67
Fisher, WE68
Brunicardi, FC69
Hodges, SE70
Reid, JG71
Drummond, J72
Chang, K73
Han, Y74
Lewis, LR75
Dinh, H76
Buhay, CJ77
Beck, T78
Timms, L79
Sam, M80
Begley, K81
Brown, A82
Pai, D83
Panchal, A84
Buchner, N85
De Borja, R86
Denroche, RE87
Yung, CK88
Serra, S89
Onetto, N90
Mukhopadhyay, D91
Tsao, MS92
Shaw, PA93
Petersen, GM94
Gallinger, S95
Hruban, RH96
Maitra, A97
Iacobuzio-Donahue, CA98
Schulick, RD99
Wolfgang, CL100
Morgan, RA101
Lawlor, RT102
Capelli, P103
Corbo, V104
Scardoni, M105
Tortora, G106
Tempero, MA107
Mann, KM108
Jenkins, NA109
Perez-Mancera, PA110
Adams, DJ111
Largaespada, DA112
Wessels, LF113
Rust, AG114
Stein, LD115
Tuveson, DA116
Copeland, NG117
Musgrove, EA118
Scarpa, A119
Eshleman, JR120
Hudson, TJ121
Sutherland, RL122
Wheeler, DA123
Pearson, JV124
McPherson, JD125
Gibbs, RA126
Grimmond, SM.127
more..
-
27
-
-
84924056345
-
Whole genomes redefine the mutational landscape of pancreatic cancer
-
27 [PMID: 25719666]
-
27 Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501 [PMID: 25719666 DOI: 10.1038/nature14169]
-
(2015)
Nature
, vol.518
, pp. 495-501
-
-
Waddell, N1
Pajic, M2
Patch, AM3
Chang, DK4
Kassahn, KS5
Bailey, P6
Johns, AL7
Miller, D8
Nones, K9
Quek, K10
Quinn, MC11
Robertson, AJ12
Fadlullah, MZ13
Bruxner, TJ14
Christ, AN15
Harliwong, I16
Idrisoglu, S17
Manning, S18
Nourse, C19
Nourbakhsh, E20
Wani, S21
Wilson, PJ22
Markham, E23
Cloonan, N24
Anderson, MJ25
Fink, JL26
Holmes, O27
Kazakoff, SH28
Leonard, C29
Newell, F30
Poudel, B31
Song, S32
Taylor, D33
Waddell, N34
Wood, S35
Xu, Q36
Wu, J37
Pinese, M38
Cowley, MJ39
Lee, HC40
Jones, MD41
Nagrial, AM42
Humphris, J43
Chantrill, LA44
Chin, V45
Steinmann, AM46
Mawson, A47
Humphrey, ES48
Colvin, EK49
Chou, A50
Scarlett, CJ51
Pinho, AV52
Giry-Laterriere, M53
Rooman, I54
Samra, JS55
Kench, JG56
Pettitt, JA57
Merrett, ND58
Toon, C59
Epari, K60
Nguyen, NQ61
Barbour, A62
Zeps, N63
Jamieson, NB64
Graham, JS65
Niclou, SP66
Bjerkvig, R67
Grützmann, R68
Aust, D69
Hruban, RH70
Maitra, A71
Iacobuzio-Donahue, CA72
Wolfgang, CL73
Morgan, RA74
Lawlor, RT75
Corbo, V76
Bassi, C77
Falconi, M78
Zamboni, G79
Tortora, G80
Tempero, MA81
Gill, AJ82
Eshleman, JR83
Pilarsky, C84
Scarpa, A85
Musgrove, EA86
Pearson, JV87
Biankin, AV88
Grimmond, SM.89
more..
-
28
-
-
79251635938
-
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
-
28 [PMID: 21248752]
-
28 Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-542 [PMID: 21248752 DOI: 10.1038/nature09639]
-
(2011)
Nature
, vol.469
, pp. 539-542
-
-
Varela, I1
Tarpey, P2
Raine, K3
Huang, D4
Ong, CK5
Stephens, P6
Davies, H7
Jones, D8
Lin, ML9
Teague, J10
Bignell, G11
Butler, A12
Cho, J13
Dalgliesh, GL14
Galappaththige, D15
Greenman, C16
Hardy, C17
Jia, M18
Latimer, C19
Lau, KW20
Marshall, J21
McLaren, S22
Menzies, A23
Mudie, L24
Stebbings, L25
Largaespada, DA26
Wessels, LF27
Richard, S28
Kahnoski, RJ29
Anema, J30
Tuveson, DA31
Perez-Mancera, PA32
Mustonen, V33
Fischer, A34
Adams, DJ35
Rust, A36
Chan-on, W37
Subimerb, C38
Dykema, K39
Furge, K40
Campbell, PJ41
Teh, BT42
Stratton, MR43
Futreal, PA.44
more..
-
29
-
-
84864444165
-
Novel mutations target distinct subgroups of medulloblastoma
-
29 [PMID: 22722829]
-
29 Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N, Baker SJ, Huether R, Kriwacki R, Curley N, Thiruvenkatam R, Wang J, Wu G, Rusch M, Hong X, Becksfort J, Gupta P, Ma J, Easton J, Vadodaria B, Onar-Thomas A, Lin T, Li S, Pounds S, Paugh S, Zhao D, Kawauchi D, Roussel MF, Finkelstein D, Ellison DW, Lau CC, Bouffet E, Hassall T, Gururangan S, Cohn R, Fulton RS, Fulton LL, Dooling DJ, Ochoa K, Gajjar A, Mardis ER, Wilson RK, Downing JR, Zhang J, Gilbertson RJ. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488: 43-48 [PMID: 22722829 DOI: 10.1038/nature11213]
-
(2012)
Nature
, vol.488
, pp. 43-48
-
-
Robinson, G1
Parker, M2
Kranenburg, TA3
Lu, C4
Chen, X5
Ding, L6
Phoenix, TN7
Hedlund, E8
Wei, L9
Zhu, X10
Chalhoub, N11
Baker, SJ12
Huether, R13
Kriwacki, R14
Curley, N15
Thiruvenkatam, R16
Wang, J17
Wu, G18
Rusch, M19
Hong, X20
Becksfort, J21
Gupta, P22
Ma, J23
Easton, J24
Vadodaria, B25
Onar-Thomas, A26
Lin, T27
Li, S28
Pounds, S29
Paugh, S30
Zhao, D31
Kawauchi, D32
Roussel, MF33
Finkelstein, D34
Ellison, DW35
Lau, CC36
Bouffet, E37
Hassall, T38
Gururangan, S39
Cohn, R40
Fulton, RS41
Fulton, LL42
Dooling, DJ43
Ochoa, K44
Gajjar, A45
Mardis, ER46
Wilson, RK47
Downing, JR48
Zhang, J49
Gilbertson, RJ.50
more..
-
30
-
-
84861427327
-
Melanoma genome sequencing reveals frequent PREX2 mutations
-
30 [PMID: 22622578]
-
30 Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carte SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485: 502-506 [PMID: 22622578 DOI: 10.1038/nature11071]
-
(2012)
Nature
, vol.485
, pp. 502-506
-
-
Berger, MF1
Hodis, E2
Heffernan, TP3
Deribe, YL4
Lawrence, MS5
Protopopov, A6
Ivanova, E7
Watson, IR8
Nickerson, E9
Ghosh, P10
Zhang, H11
Zeid, R12
Ren, X13
Cibulskis, K14
Sivachenko, AY15
Wagle, N16
Sucker, A17
Sougnez, C18
Onofrio, R19
Ambrogio, L20
Auclair, D21
Fennell, T22
Carte, SL23
Drier, Y24
Stojanov, P25
Singer, MA26
Voet, D27
Jing, R28
Saksena, G29
Barretina, J30
Ramos, AH31
Pugh, TJ32
Stransky, N33
Parkin, M34
Winckler, W35
Mahan, S36
Ardlie, K37
Baldwin, J38
Wargo, J39
Schadendorf, D40
Meyerson, M41
Gabriel, SB42
Golub, TR43
Wagner, SN44
Lander, ES45
Getz, G46
Chin, L47
Garraway, LA.48
more..
-
31
-
-
79960470568
-
GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1
-
31 [PMID: 21811562]
-
31 Zhong Y, Wang Z, Fu B, Pan F, Yachida S, Dhara M, Albesiano E, Li L, Naito Y, Vilardell F, Cummings C, Martinelli P, Li A, Yonescu R, Ma Q, Griffin CA, Real FX, Iacobuzio-Donahue CA. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. PLoS One 2011; 6: e22129 [PMID: 21811562 DOI: 10.1371/journal.pone.0022129]
-
(2011)
PLoS One
, vol.6
, pp. e22129
-
-
Zhong, Y1
Wang, Z2
Fu, B3
Pan, F4
Yachida, S5
Dhara, M6
Albesiano, E7
Li, L8
Naito, Y9
Vilardell, F10
Cummings, C11
Martinelli, P12
Li, A13
Yonescu, R14
Ma, Q15
Griffin, CA16
Real, FX17
Iacobuzio-Donahue, CA.18
-
32
-
-
12644253827
-
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas
-
32 [PMID: 8968085]
-
32 Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Ker SE. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56: 5360-5364 [PMID: 8968085]
-
(1996)
Cancer Res
, vol.56
, pp. 5360-5364
-
-
Goggins, M1
Schutte, M2
Lu, J3
Moskaluk, CA4
Weinstein, CL5
Petersen, GM6
Yeo, CJ7
Jackson, CE8
Lynch, HT9
Hruban, RH10
Ker, SE.11
-
33
-
-
83455242881
-
Genetic susceptibility to pancreatic cancer
-
33 [PMID: 22162228]
-
33 Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog 2012; 51: 14-24 [PMID: 22162228 DOI: 10.1002/mc.20855]
-
(2012)
Mol Carcinog
, vol.51
, pp. 14-24
-
-
Klein, AP.1
-
34
-
-
0037505830
-
Fanconi anemia gene mutations in young-onset pancreatic cancer
-
34 [PMID: 12750283]
-
34 van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003; 63: 2585-2588 [PMID: 12750283]
-
(2003)
Cancer Res
, vol.63
, pp. 2585-2588
-
-
van der Heijden, MS1
Yeo, CJ2
Hruban, RH3
Kern, SE.4
-
35
-
-
3042581455
-
The genetics of FANCC and FANCG in familial pancreatic cancer
-
35 [PMID: 14726700]
-
35 Rogers CD, van der Heijden MS, Brune K, Yeo CJ, Hruban RH, Kern SE, Goggins M. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther 2004; 3: 167-169 [PMID: 14726700]
-
(2004)
Cancer Biol Ther
, vol.3
, pp. 167-169
-
-
Rogers, CD1
van der Heijden, MS2
Brune, K3
Yeo, CJ4
Hruban, RH5
Kern, SE6
Goggins, M.7
-
36
-
-
12544255089
-
Germ line Fanconi anemia complementation group C mutations and pancreatic cancer
-
36 [PMID: 15695377]
-
36 Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, Petersen G. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005; 65: 383-386 [PMID: 15695377]
-
(2005)
Cancer Res
, vol.65
, pp. 383-386
-
-
Couch, FJ1
Johnson, MR2
Rabe, K3
Boardman, L4
McWilliams, R5
de Andrade, M6
Petersen, G.7
-
37
-
-
64849092309
-
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene
-
37 [PMID: 19264984]
-
37 Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217 [PMID: 19264984 DOI: 10.1126/ science.1171202]
-
(2009)
Science
, vol.324
, pp. 217
-
-
Jones, S1
Hruban, RH2
Kamiyama, M3
Borges, M4
Zhang, X5
Parsons, DW6
Lin, JC7
Palmisano, E8
Brune, K9
Jaffee, EM10
Iacobuzio-Donahue, CA11
Maitra, A12
Parmigiani, G13
Kern, SE14
Velculescu, VE15
Kinzler, KW16
Vogelstein, B17
Eshleman, JR18
Goggins, M19
Klein, AP.20
more..
-
38
-
-
84863830403
-
ATM mutations in patients with hereditary pancreatic cancer
-
38 [PMID: 22585167]
-
38 Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, Papadopoulos N, Hruban RH, Kinzler KW, Klein AP. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012; 2: 41-46 [PMID: 22585167 DOI: 10.1158/2159-8290.CD-11-0194]
-
(2012)
Cancer Discov
, vol.2
, pp. 41-46
-
-
Roberts, NJ1
Jiao, Y2
Yu, J3
Kopelovich, L4
Petersen, GM5
Bondy, ML6
Gallinger, S7
Schwartz, AG8
Syngal, S9
Cote, ML10
Axilbund, J11
Schulick, R12
Ali, SZ13
Eshleman, JR14
Velculescu, VE15
Goggins, M16
Vogelstein, B17
Papadopoulos, N18
Hruban, RH19
Kinzler, KW20
Klein, AP.21
more..
-
39
-
-
0036726313
-
Stable suppression of tumorigenicity by virus-mediated RNA interference
-
39 [PMID: 12242156]
-
39 Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-247 [PMID: 12242156]
-
(2002)
Cancer Cell
, vol.2
, pp. 243-247
-
-
Brummelkamp, TR1
Bernards, R2
Agami, R.3
-
40
-
-
22944447177
-
Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy
-
40 [PMID: 16046552]
-
40 Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005; 3: 413-423 [PMID: 16046552 DOI: 10.1158/1541-7786. MCR-04-0206]
-
(2005)
Mol Cancer Res
, vol.3
, pp. 413-423
-
-
Fleming, JB1
Shen, GL2
Holloway, SE3
Davis, M4
Brekken, RA.5
-
41
-
-
84890824325
-
Mutant KRAS is a druggable target for pancreatic cancer
-
41 [PMID: 24297898]
-
41 Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA 2013; 110: 20723-20728 [PMID: 24297898 DOI: 10.1073/pnas.1314307110]
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. 20723-20728
-
-
Zorde Khvalevsky, E1
Gabai, R2
Rachmut, IH3
Horwitz, E4
Brunschwig, Z5
Orbach, A6
Shemi, A7
Golan, T8
Domb, AJ9
Yavin, E10
Giladi, H11
Rivkin, L12
Simerzin, A13
Eliakim, R14
Khalaileh, A15
Hubert, A16
Lahav, M17
Kopelman, Y18
Goldin, E19
Dancour, A20
Hants, Y21
Arbel-Alon, S22
Abramovitch, R23
Shemi, A24
Galun, E.25
more..
-
42
-
-
84928394480
-
Cancer: The Ras renaissance
-
42 [PMID: 25877186]
-
42 Ledford H. Cancer: The Ras renaissance. Nature 2015; 520: 278-280 [PMID: 25877186 DOI: 10.1038/520278a]
-
(2015)
Nature
, vol.520
, pp. 278-280
-
-
Ledford, H.1
-
43
-
-
0030609121
-
CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents
-
43 [PMID: 9426472]
-
43 Omer CA, Kohl NE. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents. Trends Pharmacol Sci 1997; 18: 437-444 [PMID: 9426472 DOI: 10.1016/S0165-6147(97)01129-2]
-
(1997)
Trends Pharmacol Sci
, vol.18
, pp. 437-444
-
-
Omer, CA1
Kohl, NE.2
-
44
-
-
2342645506
-
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
-
44 [PMID: 15084616]
-
44 Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438 [PMID: 15084616 DOI: 10.1200/JCO.2004.10.112]
-
(2004)
J Clin Oncol
, vol.22
, pp. 1430-1438
-
-
Van Cutsem, E1
van de Velde, H2
Karasek, P3
Oettle, H4
Vervenne, WL5
Szawlowski, A6
Schoffski, P7
Post, S8
Verslype, C9
Neumann, H10
Safran, H11
Humblet, Y12
Perez Ruixo, J13
Ma, Y14
Von Hoff, D.15
-
45
-
-
26444574802
-
Development of farnesyl transferase inhibitors: a review
-
45 [PMID: 16177281]
-
45 Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist 2005; 10: 565-578 [PMID: 16177281 DOI: 10.1634/theoncologist.10-8-565]
-
(2005)
Oncologist
, vol.10
, pp. 565-578
-
-
Appels, NM1
Beijnen, JH2
Schellens, JH.3
-
46
-
-
0030923192
-
K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
-
46 [PMID: 9162087]
-
46 Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272: 14459-14464 [PMID: 9162087 DOI: 10.1074/jbc.272.22.14459]
-
(1997)
J Biol Chem
, vol.272
, pp. 14459-14464
-
-
Whyte, DB1
Kirschmeier, P2
Hockenberry, TN3
Nunez-Oliva, I4
James, L5
Catino, JJ6
Bishop, WR7
Pai, JK.8
-
47
-
-
4143060341
-
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer
-
47 [PMID: 15328183]
-
47 Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M, Rosato EF, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, Tanaka WK, Morrison B, Deutsch P, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ, Hahn SM. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 2004; 10: 5447-5454 [PMID: 15328183 DOI: 10.1158/1078-0432.CCR-04-0248]
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5447-5454
-
-
Martin, NE1
Brunner, TB2
Kiel, KD3
DeLaney, TF4
Regine, WF5
Mohiuddin, M6
Rosato, EF7
Haller, DG8
Stevenson, JP9
Smith, D10
Pramanik, B11
Tepper, J12
Tanaka, WK13
Morrison, B14
Deutsch, P15
Gupta, AK16
Muschel, RJ17
McKenna, WG18
Bernhard, EJ19
Hahn, SM.20
more..
-
48
-
-
84878401236
-
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
-
48 [PMID: 23698361]
-
48 Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens PI, Waldmann H. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013; 497: 638-642 [PMID: 23698361 DOI: 10.1038/nature12205]
-
(2013)
Nature
, vol.497
, pp. 638-642
-
-
Zimmermann, G1
Papke, B2
Ismail, S3
Vartak, N4
Chandra, A5
Hoffmann, M6
Hahn, SA7
Triola, G8
Wittinghofer, A9
Bastiaens, PI10
Waldmann, H.11
-
49
-
-
84856492497
-
The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins
-
49 [PMID: 22179043]
-
49 Chandra A, Grecco HE, Pisupati V, Perera D, Cassidy L, Skoulidis F, Ismail SA, Hedberg C, Hanzal-Bayer M, Venkitaraman AR, Wittinghofer A, Bastiaens PI. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol 2012; 14: 148-158 [PMID: 22179043 DOI: 10.1038/ncb2394]
-
(2012)
Nat Cell Biol
, vol.14
, pp. 148-158
-
-
Chandra, A1
Grecco, HE2
Pisupati, V3
Perera, D4
Cassidy, L5
Skoulidis, F6
Ismail, SA7
Hedberg, C8
Hanzal-Bayer, M9
Venkitaraman, AR10
Wittinghofer, A11
Bastiaens, PI.12
-
50
-
-
0013227128
-
A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice
-
50 [PMID: 10353601]
-
50 Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D, Gierschik P, Kloog Y. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 1999; 1 2579-2588 [PMID: 10353601 DOI: 10.1038/sj.onc.1202602]
-
(1999)
Oncogene
, vol.1
, pp. 2579-2588
-
-
Weisz, B1
Giehl, K2
Gana-Weisz, M3
Egozi, Y4
Ben-Baruch, G5
Marciano, D6
Gierschik, P7
Kloog, Y.8
-
51
-
-
84875534210
-
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer
-
51 [PMID: 22547163]
-
51 Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs 2012; 30: 2391-2399 [PMID: 22547163 DOI: 10.1007/s10637-012-9818-6]
-
(2012)
Invest New Drugs
, vol.30
, pp. 2391-2399
-
-
Laheru, D1
Shah, P2
Rajeshkumar, NV3
McAllister, F4
Taylor, G5
Goldsweig, H6
Le, DT7
Donehower, R8
Jimeno, A9
Linden, S10
Zhao, M11
Song, D12
Rudek, MA13
Hidalgo, M.14
-
52
-
-
23944439944
-
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
-
52 [PMID: 16009947]
-
52 Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23 5281-5293 [PMID: 16009947 DOI: 10.1200/JCO.2005.14.415]
-
(2005)
J Clin Oncol
, vol.23
, pp. 5281-5293
-
-
Lorusso, PM1
Adjei, AA2
Varterasian, M3
Gadgeel, S4
Reid, J5
Mitchell, DY6
Hanson, L7
DeLuca, P8
Bruzek, L9
Piens, J10
Asbury, P11
Van Becelaere, K12
Herrera, R13
Sebolt-Leopold, J14
Meyer, MB.15
-
53
-
-
77951016969
-
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer
-
53 [PMID: 20332327]
-
53 Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 2450-2457 [PMID: 20332327 DOI: 10.1158/1078-0432.CCR-09-1920]
-
(2010)
Clin Cancer Res
, vol.16
, pp. 2450-2457
-
-
Haura, EB1
Ricart, AD2
Larson, TG3
Stella, PJ4
Bazhenova, L5
Miller, VA6
Cohen, RB7
Eisenberg, PD8
Selaru, P9
Wilner, KD10
Gadgeel, SM.11
-
54
-
-
84904063663
-
A randomised, doubleblind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
-
54 [PMID: 24915778]
-
54 Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, Oh DY, Liu Y, Redhu S, Steplewski K, Le N. A randomised, doubleblind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 2014; 50: 2072-2081 [PMID: 24915778 DOI: 10.1016/j.ejca.2014.04.024]
-
(2014)
Eur J Cancer
, vol.50
, pp. 2072-2081
-
-
Infante, JR1
Somer, BG2
Park, JO3
Li, CP4
Scheulen, ME5
Kasubhai, SM6
Oh, DY7
Liu, Y8
Redhu, S9
Steplewski, K10
Le, N.11
-
55
-
-
0348049845
-
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
-
55 [PMID: 14647146]
-
55 Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003; 89: 2110-2115 [PMID: 14647146 DOI: 10.1038/sj.bjc.6601396]
-
(2003)
Br J Cancer
, vol.89
, pp. 2110-2115
-
-
Schlieman, MG1
Fahy, BN2
Ramsamooj, R3
Beckett, L4
Bold, RJ.5
-
56
-
-
4143146567
-
Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells
-
56 [PMID: 15313904]
-
56 Agbunag C, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 2004; 64: 5659-5663 [PMID: 15313904 DOI: 10.1158/0008-5472.CAN-04-0807]
-
(2004)
Cancer Res
, vol.64
, pp. 5659-5663
-
-
Agbunag, C1
Bar-Sagi, D.2
-
57
-
-
84961989770
-
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling
-
57 Jan 19; Epub ahead of print [PMID: 25601637]
-
57 Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, Jian Z, Jäger C, Regel I, Raulefs S, Behler N, Irmler M, Beckers J, Friess H, Erkan M, Siveke JT, Tannapfel A, Hahn SA, Theis FJ, Esposito I, Kleeff J, Michalski CW. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut 2015 Jan 19; Epub ahead of print [PMID: 25601637 DOI: 10.1136/ gutjnl-2014-307616]
-
(2015)
Gut
-
-
Kong, B1
Wu, W2
Cheng, T3
Schlitter, AM4
Qian, C5
Bruns, P6
Jian, Z7
Jäger, C8
Regel, I9
Raulefs, S10
Behler, N11
Irmler, M12
Beckers, J13
Friess, H14
Erkan, M15
Siveke, JT16
Tannapfel, A17
Hahn, SA18
Theis, FJ19
Esposito, I20
Kleeff, J21
Michalski, CW.22
more..
-
58
-
-
0041338049
-
Inhibition of the phosphatidylinositol 3’-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo
-
58 [PMID: 12481421]
-
58 Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3’-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1: 989-997 [PMID: 12481421]
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 989-997
-
-
Bondar, VM1
Sweeney-Gotsch, B2
Andreeff, M3
Mills, GB4
McConkey, DJ.5
-
59
-
-
78650511420
-
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo
-
59 [PMID: 20890178]
-
59 O’Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 2011; 22: 58-78 [PMID: 20890178 DOI: 10.1097/CAD.0b013e3283400a20]
-
(2011)
Anticancer Drugs
, vol.22
, pp. 58-78
-
-
O’Reilly, T1
McSheehy, PM2
Wartmann, M3
Lassota, P4
Brandt, R5
Lane, HA.6
-
60
-
-
77954478305
-
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
-
60 [PMID: 20630061]
-
60 Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010; 10: 368 [PMID: 20630061 DOI: 10.1186/1471-2407-10-368]
-
(2010)
BMC Cancer
, vol.10
, pp. 368
-
-
Javle, MM1
Shroff, RT2
Xiong, H3
Varadhachary, GA4
Fogelman, D5
Reddy, SA6
Davis, D7
Zhang, Y8
Wolff, RA9
Abbruzzese, JL.10
-
61
-
-
58249085318
-
Oral mTOR inhibitor everolimus in patients with gemcitabinerefractory metastatic pancreatic cancer
-
61 [PMID: 19047305]
-
61 Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabinerefractory metastatic pancreatic cancer. J Clin Oncol 2009; 27: 193-198 [PMID: 19047305 DOI: 10.1200/JCO.2008.18.9514]
-
(2009)
J Clin Oncol
, vol.27
, pp. 193-198
-
-
Wolpin, BM1
Hezel, AF2
Abrams, T3
Blaszkowsky, LS4
Meyerhardt, JA5
Chan, JA6
Enzinger, PC7
Allen, B8
Clark, JW9
Ryan, DP10
Fuchs, CS.11
-
62
-
-
84905579496
-
Targeting mTOR dependency in pancreatic cancer
-
62 [PMID: 24717934]
-
62 Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ, Oien KA, McKay CJ, Carter CR, Gillen G, Champion S, Pimlott SL, Anderson KI, Evans TR, Grimmond SM, Biankin AV, Sansom OJ, Morton JP. Targeting mTOR dependency in pancreatic cancer. Gut 2014; 63: 1481-1489 [PMID: 24717934 DOI: 10.1136/gutjnl-2013-306202]
-
(2014)
Gut
, vol.63
, pp. 1481-1489
-
-
Morran, DC1
Wu, J2
Jamieson, NB3
Mrowinska, A4
Kalna, G5
Karim, SA6
Au, AY7
Scarlett, CJ8
Chang, DK9
Pajak, MZ10
Oien, KA11
McKay, CJ12
Carter, CR13
Gillen, G14
Champion, S15
Pimlott, SL16
Anderson, KI17
Evans, TR18
Grimmond, SM19
Biankin, AV20
Sansom, OJ21
Morton, JP.22
more..
-
63
-
-
84862731796
-
Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer
-
63 [PMID: 22411900]
-
63 Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold J. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther 2012; 11: 1193-1202 [PMID: 22411900 DOI: 10.1158/1535-7163.MCT-12-0098]
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 1193-1202
-
-
Williams, TM1
Flecha, AR2
Keller, P3
Ram, A4
Karnak, D5
Galbán, S6
Galbán, CJ7
Ross, BD8
Lawrence, TS9
Rehemtulla, A10
Sebolt-Leopold, J.11
-
64
-
-
84921064807
-
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer
-
64 [PMID: 25348516]
-
64 Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes C, Engelman JA, Bardeesy N. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res 2015; 21: 396-404 [PMID: 25348516 DOI: 10.1158/1078-0432.CCR-14-1591]
-
(2015)
Clin Cancer Res
, vol.21
, pp. 396-404
-
-
Alagesan, B1
Contino, G2
Guimaraes, AR3
Corcoran, RB4
Deshpande, V5
Wojtkiewicz, GR6
Hezel, AF7
Wong, KK8
Loda, M9
Weissleder, R10
Benes, C11
Engelman, JA12
Bardeesy, N.13
-
65
-
-
84876969576
-
Significance of Notch1-signaling pathway in human pancreatic development and carcinogenesis
-
65 [PMID: 23235341]
-
65 Hu H, Zhou L, Awadallah A, Xin W. Significance of Notch1-signaling pathway in human pancreatic development and carcinogenesis. Appl Immunohistochem Mol Morphol 2013; 21: 242-247 [PMID: 23235341 DOI: 10.1097/PAI.0b013e3182655ab7]
-
(2013)
Appl Immunohistochem Mol Morphol
, vol.21
, pp. 242-247
-
-
Hu, H1
Zhou, L2
Awadallah, A3
Xin, W.4
-
66
-
-
84860374357
-
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
-
66 [PMID: 22351932]
-
66 Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T, Howat WJ, Jodrell DI, Tuveson DA. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 2012; 209: 437-444 [PMID: 22351932 DOI: 10.1084/jem.20111923]
-
(2012)
J Exp Med
, vol.209
, pp. 437-444
-
-
Cook, N1
Frese, KK2
Bapiro, TE3
Jacobetz, MA4
Gopinathan, A5
Miller, JL6
Rao, SS7
Demuth, T8
Howat, WJ9
Jodrell, DI10
Tuveson, DA.11
-
67
-
-
84881112879
-
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma
-
67 [PMID: 23847203]
-
67 Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, Smith TR, Avello M, Charlat O, Xie Y, Porter JA, Pan S, Liu J, McLaughlin ME, Cong F. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 2013; 110: 12649-12654 [PMID: 23847203 DOI: 10.1073/ pnas.1307218110]
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. 12649-12654
-
-
Jiang, X1
Hao, HX2
Growney, JD3
Woolfenden, S4
Bottiglio, C5
Ng, N6
Lu, B7
Hsieh, MH8
Bagdasarian, L9
Meyer, R10
Smith, TR11
Avello, M12
Charlat, O13
Xie, Y14
Porter, JA15
Pan, S16
Liu, J17
McLaughlin, ME18
Cong, F.19
-
68
-
-
52649169761
-
Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer
-
68 [PMID: 18515410]
-
68 Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, Ouellette MM, Yu W, Maitra A. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008; 57: 1420-1430 [PMID: 18515410 DOI: 10.1136/gut.2007.148189]
-
(2008)
Gut
, vol.57
, pp. 1420-1430
-
-
Feldmann, G1
Habbe, N2
Dhara, S3
Bisht, S4
Alvarez, H5
Fendrich, V6
Beaty, R7
Mullendore, M8
Karikari, C9
Bardeesy, N10
Ouellette, MM11
Yu, W12
Maitra, A.13
-
69
-
-
79953702542
-
Hedgehog signaling and therapeutics in pancreatic cancer
-
69 [PMID: 21186299]
-
69 Kelleher FC. Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 2011; 32: 445-451 [PMID: 21186299 DOI: 10.1093/carcin/bgq280]
-
(2011)
Carcinogenesis
, vol.32
, pp. 445-451
-
-
Kelleher, FC.1
-
70
-
-
54049115162
-
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer
-
70 [PMID: 18790753]
-
70 Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra JB, Habbe N, Karikari C, Mullendore M, Gabrielson KL, Sharma R, Matsui W, Maitra A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008; 7: 2725-2735 [PMID: 18790753 DOI: 10.1158/1535-7163. MCT-08-0573]
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2725-2735
-
-
Feldmann, G1
Fendrich, V2
McGovern, K3
Bedja, D4
Bisht, S5
Alvarez, H6
Koorstra, JB7
Habbe, N8
Karikari, C9
Mullendore, M10
Gabrielson, KL11
Sharma, R12
Matsui, W13
Maitra, A.14
-
71
-
-
67149143399
-
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
-
71 [PMID: 19460966]
-
71 Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland- Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461 [PMID: 19460966 DOI: 10.1126/ science.1171362]
-
(2009)
Science
, vol.324
, pp. 1457-1461
-
-
Olive, KP1
Jacobetz, MA2
Davidson, CJ3
Gopinathan, A4
McIntyre, D5
Honess, D6
Madhu, B7
Goldgraben, MA8
Caldwell, ME9
Allard, D10
Frese, KK11
Denicola, G12
Feig, C13
Combs, C14
Winter, SP15
Ireland- Zecchini, H16
Reichelt, S17
Howat, WJ18
Chang, A19
Dhara, M20
Wang, L21
Rückert, F22
Grützmann, R23
Pilarsky, C24
Izeradjene, K25
Hingorani, SR26
Huang, P27
Davies, SE28
Plunkett, W29
Egorin, M30
Hruban, RH31
Whitebread, N32
McGovern, K33
Adams, J34
Iacobuzio-Donahue, C35
Griffiths, J36
Tuveson, DA.37
more..
-
72
-
-
84930046983
-
Stromal uncertainties in pancreatic cancer
-
72
-
72 Lou KJ. Stromal uncertainties in pancreatic cancer. SciBX 2014; 7: 23
-
(2014)
SciBX
, vol.7
, pp. 23
-
-
Lou, KJ.1
-
73
-
-
0029041032
-
Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region
-
73 [PMID: 7597059]
-
73 Schutte M, da Costa LT, Hahn SA, Moskaluk C, Hoque AT, Rozenblum E, Weinstein CL, Bittner M, Meltzer PS, Trent JM. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 1995; 92: 5950-5954 [PMID: 7597059 DOI: 10.1073/pnas.92.13.5950]
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 5950-5954
-
-
Schutte, M1
da Costa, LT2
Hahn, SA3
Moskaluk, C4
Hoque, AT5
Rozenblum, E6
Weinstein, CL7
Bittner, M8
Meltzer, PS9
Trent, JM.10
-
74
-
-
18444362122
-
Biallelic inactivation of BRCA2 in Fanconi anemia
-
74 [PMID: 12065746]
-
74 Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D’Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-609 [PMID: 12065746 DOI: 10.1126/science.1073834]
-
(2002)
Science
, vol.297
, pp. 606-609
-
-
Howlett, NG1
Taniguchi, T2
Olson, S3
Cox, B4
Waisfisz, Q5
De Die-Smulders, C6
Persky, N7
Grompe, M8
Joenje, H9
Pals, G10
Ikeda, H11
Fox, EA12
D’Andrea, AD.13
-
75
-
-
67650471685
-
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
-
75 [PMID: 19553641]
-
75 Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134 [PMID: 19553641 DOI 10.1056/NEJMoa0900212]
-
(2009)
N Engl J Med
, vol.361
, pp. 123-134
-
-
Fong, PC1
Boss, DS2
Yap, TA3
Tutt, A4
Wu, P5
Mergui-Roelvink, M6
Mortimer, P7
Swaisland, H8
Lau, A9
O’Connor, MJ10
Ashworth, A11
Carmichael, J12
Kaye, SB13
Schellens, JH14
de Bono, JS.15
-
76
-
-
3242789247
-
Functional defects in the fanconi anemia pathway in pancreatic cancer cells
-
76 [PMID: 15277238]
-
76 van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004; 165: 651-657 [PMID: 15277238 DOI: 10.1016/ S0002-9440(10)63329-9]
-
(2004)
Am J Pathol
, vol.165
, pp. 651-657
-
-
van der Heijden, MS1
Brody, JR2
Gallmeier, E3
Cunningham, SC4
Dezentje, DA5
Shen, D6
Hruban, RH7
Kern, SE.8
-
77
-
-
78751559414
-
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer
-
77 [PMID: 21135251]
-
77 Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011; 10: 3-8 [PMID: 21135251 DOI: 10.1158/1535-7163.MCT-10-0893]
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 3-8
-
-
Villarroel, MC1
Rajeshkumar, NV2
Garrido-Laguna, I3
De Jesus-Acosta, A4
Jones, S5
Maitra, A6
Hruban, RH7
Eshleman, JR8
Klein, A9
Laheru, D10
Donehower, R11
Hidalgo, M.12
-
78
-
-
33748065304
-
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
-
78 [PMID: 16912188]
-
78 McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O’Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-8115 [PMID: 16912188 DOI: 10.1158/0008-5472.CAN-06-0140]
-
(2006)
Cancer Res
, vol.66
, pp. 8109-8115
-
-
McCabe, N1
Turner, NC2
Lord, CJ3
Kluzek, K4
Bialkowska, A5
Swift, S6
Giavara, S7
O’Connor, MJ8
Tutt, AN9
Zdzienicka, MZ10
Smith, GC11
Ashworth, A.12
-
79
-
-
84928248330
-
Personalized genomic analyses for cancer mutation discovery and interpretation
-
79 [PMID: 25877891]
-
79 Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, Galens KG, Murphy D, Zhang T, Kann L, Sausen M, Angiuoli SV, Diaz LA, Velculescu VE. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 2015; 7: 283ra53 [PMID: 25877891 DOI: 10.1126/scitranslmed.aaa7161]
-
(2015)
Sci Transl Med
, vol.7
, pp. 283ra53
-
-
Jones, S1
Anagnostou, V2
Lytle, K3
Parpart-Li, S4
Nesselbush, M5
Riley, DR6
Shukla, M7
Chesnick, B8
Kadan, M9
Papp, E10
Galens, KG11
Murphy, D12
Zhang, T13
Kann, L14
Sausen, M15
Angiuoli, SV16
Diaz, LA17
Velculescu, VE.18
-
80
-
-
84881474788
-
Understanding pancreatic cancer genomes
-
80 [PMID: 23660961]
-
80 Cowley MJ, Chang DK, Pajic M, Johns AL, Waddell N, Grimmond SM, Biankin AV. Understanding pancreatic cancer genomes. J Hepatobiliary Pancreat Sci 2013; 20: 549-556 [PMID: 23660961 DOI: 10.1007/s00534-013-0610-6]
-
(2013)
J Hepatobiliary Pancreat Sci
, vol.20
, pp. 549-556
-
-
Cowley, MJ1
Chang, DK2
Pajic, M3
Johns, AL4
Waddell, N5
Grimmond, SM6
Biankin, AV.7
-
81
-
-
78049398107
-
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
-
81 [PMID: 20981102]
-
81 Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117 [PMID: 20981102 DOI: 10.1038/ nature09515]
-
(2010)
Nature
, vol.467
, pp. 1114-1117
-
-
Yachida, S1
Jones, S2
Bozic, I3
Antal, T4
Leary, R5
Fu, B6
Kamiyama, M7
Hruban, RH8
Eshleman, JR9
Nowak, MA10
Velculescu, VE11
Kinzler, KW12
Vogelstein, B13
Iacobuzio-Donahue, CA.14
-
82
-
-
84896371874
-
Detection of circulating tumor DNA in early- and latestage human malignancies
-
82 [PMID: 24553385]
-
82 Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA. Detection of circulating tumor DNA in early- and latestage human malignancies. Sci Transl Med 2014; 6: 224ra24 [PMID: 24553385 DOI: 10.1126/scitranslmed.3007094]
-
(2014)
Sci Transl Med
, vol.6
, pp. 224ra24
-
-
Bettegowda, C1
Sausen, M2
Leary, RJ3
Kinde, I4
Wang, Y5
Agrawal, N6
Bartlett, BR7
Wang, H8
Luber, B9
Alani, RM10
Antonarakis, ES11
Azad, NS12
Bardelli, A13
Brem, H14
Cameron, JL15
Lee, CC16
Fecher, LA17
Gallia, GL18
Gibbs, P19
Le, D20
Giuntoli, RL21
Goggins, M22
Hogarty, MD23
Holdhoff, M24
Hong, SM25
Jiao, Y26
Juhl, HH27
Kim, JJ28
Siravegna, G29
Laheru, DA30
Lauricella, C31
Lim, M32
Lipson, EJ33
Marie, SK34
Netto, GJ35
Oliner, KS36
Olivi, A37
Olsson, L38
Riggins, GJ39
Sartore-Bianchi, A40
Schmidt, K41
Shih, lM42
Oba-Shinjo, SM43
Siena, S44
Theodorescu, D45
Tie, J46
Harkins, TT47
Veronese, S48
Wang, TL49
Weingart, JD50
Wolfgang, CL51
Wood, LD52
Xing, D53
Hruban, RH54
Wu, J55
Allen, PJ56
Schmidt, CM57
Choti, MA58
Velculescu, VE59
Kinzler, KW60
Vogelstein, B61
Papadopoulos, N62
Diaz, LA.63
more..
-
83
-
-
84900992934
-
Detection of cancer DNA in plasma of patients with earlystage breast cancer
-
83 [PMID: 24504125]
-
83 Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, Wong HY, Valda Toro P, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg DA, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH. Detection of cancer DNA in plasma of patients with earlystage breast cancer. Clin Cancer Res 2014; 20: 2643-2650 [PMID: 24504125 DOI: 10.1158/1078-0432.CCR-13-2933]
-
(2014)
Clin Cancer Res
, vol.20
, pp. 2643-2650
-
-
Beaver, JA1
Jelovac, D2
Balukrishna, S3
Cochran, RL4
Croessmann, S5
Zabransky, DJ6
Wong, HY7
Valda Toro, P8
Cidado, J9
Blair, BG10
Chu, D11
Burns, T12
Higgins, MJ13
Stearns, V14
Jacobs, L15
Habibi, M16
Lange, J17
Hurley, PJ18
Lauring, J19
VanDenBerg, DA20
Kessler, J21
Jeter, S22
Samuels, ML23
Maar, D24
Cope, L25
Cimino-Mathews, A26
Argani, P27
Wolff, AC28
Park, BH.29
more..
-
84
-
-
84903218109
-
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
-
84 [PMID: 24705333]
-
84 Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW, Alizadeh AA, Diehn M. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20: 548-554 [PMID: 24705333 DOI: 10.1038/nm.3519]
-
(2014)
Nat Med
, vol.20
, pp. 548-554
-
-
Newman, AM1
Bratman, SV2
To, J3
Wynne, JF4
Eclov, NC5
Modlin, LA6
Liu, CL7
Neal, JW8
Wakelee, HA9
Merritt, RE10
Shrager, JB11
Loo, BW12
Alizadeh, AA13
Diehn, M.14
|